Underpinning modern biologics R&D, and products and the discovery/development of small molecule drug are the purified recombinant proteins and DNA plasmids that express these proteins. Rapid translation of discoveries in genomics, proteomics and high throughput screening into potential commercial products - drugs, vaccines, and diagnostics- requires a robust, high quality protein development and production process that takes molecules from discovery through initiation of clinical trials. Protein Potential is inthebusiness of providing the high quality, purified Protein PotentialTM recombinant proteins and DNA plasmids. Thefirm also offers process development, documentation, and technological know-how to transition therapeutic, vaccine, diagnostic proteins and DNA plasmids to large scale cGMP (Good Manufacturing Practices) manufacture (Protein Potential,SM service packages). The firm's competitive advantage lies in the experience and capabilities rapidly and efficiently to take newly discovered molecules through all of the steps required to initiate a clinical trial. These include initial protein expression, enhanced protein expression, process development for cGMP manufacture, development of analytical assays, transition to a cGMP site, and other processes for investigational new drug (IND) enabling studies. Protein Potentials staff have been responsible for the cGMP manufacture of tens of kilograms of purified recombinant proteins that have been administered intravenously to patients. The firm also offers customized packages of purified proteins (milligram to gram quantities), development and testing of analytical assays, development of manufacturing processes, process development documentation, consultation, and hands-on involvement in a highly competitive timeframe and at a fair price. Protein Potential undertakes R&D to produce IP, DNA and protein products. A program has been intiated to produce vaccines for SARS, dengue fever, tularemia, Plasmodium falciparum malaria and Plasmodium vivax malaria. The firm's R&D team focuses on vaccine development with internal programs intended to produce vaccines for Plasmodium vivax malaria, Plasmodium falciparum malaria, SARS, dengue fever, tularemia, and plague.
